0J8Z Stock Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0J8Z from our risk checks.
My Notes
NewNotes are coming soon
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$199.40 |
| 52 Week High | US$369.46 |
| 52 Week Low | US$173.30 |
| Beta | 1.13 |
| 1 Month Change | 3.16% |
| 3 Month Change | -8.95% |
| 1 Year Change | -46.57% |
| 3 Year Change | -40.43% |
| 5 Year Change | n/a |
| Change since IPO | -18.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0J8Z | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 1.6% | -9.4% | -1.0% |
| 1Y | -46.6% | -43.9% | -5.8% |
Return vs Industry: 0J8Z underperformed the UK Life Sciences industry which returned -43.9% over the past year.
Return vs Market: 0J8Z underperformed the UK Market which returned -5.8% over the past year.
Price Volatility
| 0J8Z volatility | |
|---|---|
| 0J8Z Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0J8Z is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 0J8Z's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 9,825 | Francis deSouza | https://www.illumina.com |
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.
Illumina, Inc. Fundamentals Summary
| 0J8Z fundamental statistics | |
|---|---|
| Market Cap | US$32.15b |
| Earnings (TTM) | -US$4.15b |
| Revenue (TTM) | US$4.70b |
6.8x
P/S Ratio-7.7x
P/E RatioIs 0J8Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0J8Z income statement (TTM) | |
|---|---|
| Revenue | US$4.70b |
| Cost of Revenue | US$1.42b |
| Gross Profit | US$3.28b |
| Other Expenses | US$7.44b |
| Earnings | -US$4.15b |
Last Reported Earnings
Oct 02, 2022
Next Earnings Date
Feb 07, 2023
| Earnings per share (EPS) | -26.40 |
| Gross Margin | 69.83% |
| Net Profit Margin | -88.36% |
| Debt/Equity Ratio | 25.9% |
How did 0J8Z perform over the long term?
See historical performance and comparison